NYSEHealth CareHealth Care FacilitiesS&P SmallCap 600
$99.49
+2.29 (+2.36%)
Close of Nov 06, 2026 · end-of-day data
USPH 8-K filings in 2025
Every material Form 8-K U.S. Physical Therapy filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
U.S. Physical Therapy reported third-quarter 2025 results, with physical therapy revenue up 17.8% to $168.1 million and net income attributable to shareholders rising to $13.1 million, or $0.48 per share, from $6.6 million, or $0.39 per share, a year earlier. Management reaffirmed its full-year 2025 Adjusted EBITDA guidance of $93.0 million to $97.0 million and declared a $0.45 quarterly dividend.
Physical therapy revenue rose 17.8% to $168.1 million; patient visits rose 18.0% to 1,554,207.
Net income attributable to USPH shareholders was $13.1 million ($0.48 per share) vs. $6.6 million ($0.39 per share) a year earlier.
Operating Results, a non-GAAP measure, fell to $10.1 million ($0.66 per share) from $10.4 million ($0.69 per share).
Full-year 2025 Adjusted EBITDA guidance of $93.0 million to $97.0 million was reaffirmed; $0.45 dividend payable December 12, 2025 to holders of record November 17, 2025.
U.S. Physical Therapy reported second quarter 2025 results with revenue of $168.3 million, up 17.3% from a year earlier, and net income attributable to shareholders of $12.4 million, or $0.58 per share, versus $7.5 million, or $0.47 per share, a year ago. The company raised its full-year 2025 Adjusted EBITDA guidance to $93.0 million to $97.0 million and declared a $0.45 quarterly dividend.
Q2 2025 Adjusted EBITDA was $26.9 million, up 21.4% from $22.1 million in Q2 2024.
Full-year 2025 Adjusted EBITDA guidance raised to a range of $93.0 million to $97.0 million.
Quarterly dividend of $0.45 per share payable September 12, 2025, to holders of record on August 22, 2025.
Board approved a share repurchase program of up to $25 million through December 31, 2026.
At its annual meeting on May 20, 2025, U.S. Physical Therapy shareholders elected all eight director nominees and approved the advisory vote on named executive officer compensation. They also ratified Grant Thornton LLP as the independent registered public accounting firm for 2024. The filing reports routine shareholder votes, with no change in results or financial measures.
Eight directors elected, including Dr. Bernard A. Harris, Jr. (12,422,647 for; 1,175,315 withheld) and Nancy J. Ham (13,500,869 for; 97,093 withheld)
U.S. Physical Therapy reported first-quarter 2025 results for the period ended March 31, 2025. Revenue from physical therapy operations rose 16.4% to $156.4 million, and earnings per share attributable to shareholders were $0.80, compared with $0.46 a year earlier, while non-GAAP Operating Results per share fell to $0.48 from $0.51. The board also declared a $0.45 quarterly dividend.
Revenue from physical therapy operations rose $22.0 million, or 16.4%, to $156.4 million.
Net income attributable to USPH shareholders was $9.9 million, or $0.80 per share, versus $8.0 million, or $0.46 per share, a year earlier.
Non-GAAP Operating Results were $7.3 million, or $0.48 per share, versus $7.7 million, or $0.51 per share, in the prior-year quarter.
Quarterly dividend of $0.45 per share is payable June 13, 2025, to shareholders of record on May 23, 2025.
On March 26, 2025, the Compensation Committee of U.S. Physical Therapy's board approved four 2025 incentive plans for senior management, covering long-term equity awards and cash or stock bonuses. Awards depend on 2025 Adjusted EBITDA targets, with grants and bonus decisions set for the first quarter of 2026, so the plans tie executive pay to future earnings performance.
Maximum long-term restricted stock awards: CEO Christopher Reading 12,500 shares; President Eric Williams 7,500 shares; CFO Carey Hendrickson, COO West Graham Reeve and EVP Rick Binstein 5,000 shares each.
Objective bonus up to 100% of base salary for the CEO and up to 75% for other eligible executives; awards to be determined in the first quarter of 2026.
Awards vest evenly over 16 quarters, beginning May 20, 2026, with final vesting on March 6, 2030.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every U.S. Physical Therapy filing is on SEC EDGAR ↗. 8-K briefs of other companies →